Prognostic Prediction in Patients with Hepatocellular Carcinoma

Margarita Sala; Alejandro Forner; Maria Varela; Jordi Bruix

doi:10.1055/s-2005-871197

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2005; 25(2): 171-180
DOI: 10.1055/s-2005-871197

Prognostic Prediction in Patients with Hepatocellular Carcinoma

Margarita Sala¹ , Alejandro Forner¹ , Maria Varela¹ , Jordi Bruix¹ ^, ²

¹Liver Unit, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
²Senior Consultant and Associate Professor of Medicine

Abstract

ABSTRACT

With most solid tumors, the estimation of life expectancy is related to tumor stage at diagnosis and staging is directly linked to treatment indication. By contrast, in patients with hepatocellular carcinoma (HCC) the prediction of prognosis is more complex. There is no worldwide consensus on the use of any HCC staging system. Classifications that take into account only one of the relevant prognostic parameters, such as tumor, nodes, and metastasis (TNM) or Child-Pugh staging, are useless. Several scoring systems have been developed, but unfortunately their major capacity is to identify end-stage patients and they do not link staging with therapy. The Barcelona Clinic Liver Cancer (BCLC) staging system was developed according to the results of cohort studies and randomized clinical trials. It considers tumor stage, liver functional status, physical status, and cancer-related symptoms and, by dividing patients into early, intermediate, advanced, and end-stage categories, provides a link to treatment indication.

KEYWORDS

Hepatocellular carcinoma - staging - prognosis - treatment

Volltext

Referenzen

REFERENCES

1 Bruix J, Sherman M, Llovet J M et al.. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001; 35 421-430
2 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127(5 suppl 1) S35-S50
3 American Joint Committee on Cancer. AJCC Cancer Staging Handbook. New York; Springer 2002
4 Pugh R N, Murray-Lyon I M, Dawson J L et al.. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60 646-649
5 Kamath P S, Wiesner R H, Malinchoc M et al.. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33 464-470
6 Sorensen J B, Klee M, Palshof T, Hansen H H. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993; 67 773-775
7 Schag C C, Heinrich R L, Ganz P A. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984; 2 187-193
8 Primack A, Vogel C L, Kyalwazi S K et al.. A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients. Cancer. 1975; 35 1357-1364
9 Chlebowski R T, Tong M, Weissman J et al.. Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. Cancer. 1984; 53 2701-2706
10 Attali P, Prod'Homme S, Pelletier G et al.. Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer. 1987; 59 2108-2111
11 Falkson G, Cnaan A, Schutt A J et al.. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res. 1988; 48 7314-7318
12 Calvet X, Bruix J, Gines P et al.. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology. 1990; 12 753-760
13 Stuart K E, Anand A J, Jenkins R L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 1996; 77 2217-2222
14 A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28 751-755
15 Llovet J M, Bustamante J, Castells A et al.. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999; 29 62-67
16 Villa E, Moles A, Ferretti I et al.. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000; 32 233-238
17 Llovet J M, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19 329-338
18 Chevret S, Trinchet J C, Mathieu D et al.. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol. 1999; 31 133-141
19 Leung T W, Tang A M, Zee B et al.. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002; 94 1760-1769
20 Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003; 38 207-215
21 Omagari K, Honda S, Kadokawa Y et al.. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol. 2004; 19 805-811
22 Tateishi R, Yoshida H, Shiina S et al.. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005; 54 419-425
23 Altman D G, Royston P. What do we mean by validating a prognostic model?. Stat Med. 2000; 19 453-473
24 Okuda K, Ohtsuki T, Obata H et al.. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56 918-928
25 Schoniger-Hekele M, Muller C, Kutilek M et al.. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001; 48 103-109
26 Herold C, Reck T, Fischler P et al.. Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver. 2002; 22 23-28
27 Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 2000; 31 840-845
28 Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000; 89 2266-2273
29 Ueno S, Tanabe G, Sako K et al.. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001; 34 529-534
30 Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002; 50 881-885
31 Kudo M, Chung H, Haji S et al.. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004; 40 1396-1405
32 Grieco A, Pompili M, Caminiti G et al.. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005; 54 411-418
33 Marrero J, Fontana R, Barrat A et al.. Prognosis of hepatocellular carcinoma: comparison of seven staging systems in an American cohort. Hepatology. 2005; 41 707-716
34 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362 1907-1917
35 Cillo U, Bassanello M, Vitale A et al.. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. J Hepatol. 2004; 40 124-131
36 Barbara L, Benzi G, Gaiani S et al.. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992; 16 132-137
37 Livraghi T, Bolondi L, Buscarini L et al.. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol. 1995; 22 522-526
38 Ebara M, Ohto M, Shinagawa T et al.. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986; 90 289-298
39 Bruix J, Llovet J M, Castells A et al.. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998; 27 1578-1583
40 Castells A, Bruix J, Bru C et al.. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 1995; 109 917-922
41 Llovet J M, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30 1434-1440
42 Wayne J D, Lauwers G Y, Ikai I et al.. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002; 235 722-730
43 Vauthey J N, Lauwers G Y, Esnaola N F et al.. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002; 20 1527-1536
44 Ikai I, Arii S, Kojiro M et al.. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004; 101 796-802
45 Torzilli G, Makuuchi M, Inoue K et al.. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg. 1999; 134 984-992
46 Bruix J, Castells A, Bosch J et al.. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996; 111 1018-1022
47 Poon R T, Fan S T, Ng I O et al.. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 89 500-507
48 Imamura H, Matsuyama Y, Tanaka E et al.. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38 200-207
49 Mazzaferro V, Regalia E, Doci R et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334 693-699
50 Plessier A, Codes L, Consigny Y et al.. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl. 2004; 10(suppl 2) S86-S90
51 Sala M, Llovet J M, Vilana R et al.. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004; 40 1352-1360
52 Llovet J M, Real M I, Montanya X et al.. Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002; 359 1734-1739
53 Bruix J, Boix L, Sala M, Llovet J M. Focus on hepatocellular carcinoma. Cancer Cell. 2004; 5 215-219
54 Takayama T, Makuuchi M, Hirohashi S et al.. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998; 28 1241-1246

Jordi BruixM.D.

BCLC Group. Liver Unit, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer

Villarroel 170, 08036 Barcelona, Spain

eMail: bruix@ub.edu